Chrysos Secures Breakthrough Global Deal with Newmont for PhotonAssay™ Rollout

About Chrysos Corporation Limited

Chrysos Corporation Ltd (ASX: C79) is an Australian-based industrial technology company delivering advanced material analysis solutions to the mining sector. Its flagship product, PhotonAssay™, offers a faster, safer, and more environmentally friendly alternative to traditional fire assay techniques for measuring gold and other valuable metals. With an expanding presence across Australia, Africa, and the Americas, Chrysos partners with global miners and laboratory networks to deploy PhotonAssay™ units at production sites and testing facilities. The company listed on the ASX in 2022 and continues to attract attention for its innovative technology and recurring revenue model.

Newmont Partnership Marks Global Validation of PhotonAssay™

Chrysos Corporation has taken a major leap forward in its global growth ambitions through a new Master Services Agreement (MSA) with Newmont Corporation, the world’s largest gold producer. Under the terms of the agreement, Newmont has committed to installing its first PhotonAssay™ unit at the Ahafo gold mine in Ghana, a flagship West African operation. The installation is expected to be completed and operational by first half FY26.

This agreement follows a successful six-month trial of PhotonAssay™ at Newmont’s Tanami mine in Australia, which demonstrated high reliability and operational performance. The global MSA enables further deployment of Chrysos’s technology across Newmont’s sites globally, with Ghana representing the first formal commercial rollout. The company views this not only as a validation of its technology by a Tier 1 mining major but also a gateway for future site expansion.

The PhotonAssay™ unit destined for Ahafo will be installed and operated by Chrysos’s global deployment partner, MSALABS, aligning with the company’s existing strategy to scale through third-party labs and service providers.

This development is particularly significant because it accelerates Chrysos’s commercial rollout and brings in long-term contracted revenue. Each PhotonAssay™ unit contributes multi-year recurring revenue under service agreements, making the Newmont deal strategically accretive to the company’s future cash flow outlook.

Shares Surge as Investors React to Strategic Global Expansion

Investor sentiment toward Chrysos has turned positive following the Newmont announcement. Shares climbed to $4.30, up 4.12%, reflecting market confidence in the company’s ability to secure and execute high-profile contracts.

Despite a -24.03% one-year return, the Newmont deal is a clear inflection point that could reverse recent underperformance. Chrysos now ranks 490 out of 2,324 on the ASX and 49 out of 203 in the industrials sector. Its market capitalisation stands at $497.98 million, underlining its small-to-mid cap positioning — a level where strategic partnerships can have outsized impact on valuation.

The company’s PE ratio of 4,300 reflects limited earnings relative to price, due largely to reinvestment in growth and R&D. However, as PhotonAssay™ units are deployed and begin generating recurring service income, profitability metrics are expected to normalise.

The long-term commercial viability of PhotonAssay™ is rooted in its ability to replace traditional fire assay with a faster, more accurate, and safer solution — a trend that aligns with the mining sector’s push toward operational efficiency and ESG compliance.

With over 50 PhotonAssay™ units targeted for global deployment by FY27, the partnership with Newmont could unlock broader market acceptance. Investors will be watching closely for follow-on deployments or new site activations under the MSA framework.

Chrysos is now better positioned than ever to become a globally recognised provider of next-generation mining assay solutions. The Newmont deal confirms the company’s credibility and marks the beginning of what could be a new growth phase supported by global mining giants.